You can buy or sell HALO and other stocks, options, ETFs, and crypto commission-free!
Halozyme Therapeutics, Inc. Common Stock, also called Halozyme Therapeutics, is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. Read More It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Yahoo FinanceMay 13
Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019
SAN DIEGO, May 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the Bank of America Merrill Lynch Health Care Conference 2019 in Las Vegas, NV. Laurie Stelzer, senior vice president and chief financial officer, will provide an overview of the company on Thursday, May 16 at 12:20 p.m. ET / 9:20 a.m. PT. A live webcast of the presentation can be accessed through the "Investors" section of www.halozy...
Halozyme Therapeutics Inc (HALO) Q1 2019 Earnings Call Transcript
Image source: The Motley Fool. Halozyme Therapeutics Inc (NASDAQ: HALO) Q1 2019 Earnings Call May. 7, 2019 , 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon, everyone. I would now like to turn the conference over to Al Kildani, Vice President of Investor Relations and Corporate Communications for Halozyme Therapeutics. Mr. Kildani, please begin. Al Kildani -- Vice President of Investor Relations and Corporate Communications...
$0.01 per share
$0.01 per share